News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Ark Therapeutics’ Phase III Brain Cancer Drug Trial Cleared To Continue Update
January 5, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (AFX) - Ark Therapeutics Group PLC's final-stage trial of an experimental drug to treat brain cancer has been cleared to continue without modification, by Europe's medicine safety board.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Regulatory
Europe
MORE ON THIS TOPIC
Cancer
BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
August 28, 2026
·
2 min read
·
Heather McKenzie
cardiovascular disease
‘Worse than expected’ Wainua data muddies water for TTR silencers
August 28, 2026
·
2 min read
·
Gabrielle Masson
FDA
Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist Mounjaro
August 28, 2026
·
2 min read
·
Heather McKenzie
Insights
Multispecifics are transforming the CDMO development architecture
August 28, 2026
·
6 min read
·
Jennifer C. Smith-Parker
